Viread aims at KRW 100 billion sales as exceeding KRW 50 billion only in the first half of the year
The Gilead’s chronic hepatitis type B treatment, ‘Viread(generic name: tenofovir)’ is expected to make a sales record worth of KRW 50 billion only in the first half of the year.
According to the Yuhan Corporation’s company report written by NH Investment & Securities on the basis of the UBIST LI...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
